科华生物：关于不向下修正“科华转债”转股价格的公告

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds, "Kehua Convertible Bonds," and will not propose any downward adjustments for the next six months [2]. Summary by Relevant Sections - Board Meeting Decision: On August 22, 2025, the company's board of directors held the fifteenth meeting of the tenth session and approved the proposal not to adjust the conversion price of "Kehua Convertible Bonds" downward [2]. - Future Adjustments: The company will not propose any downward adjustment to the conversion price even if the conditions for such adjustments are triggered again within the next six months, from August 23, 2025, to February 22, 2026 [2]. - Post Six-Month Review: After the six-month period, starting from February 23, 2026, if the conditions for downward adjustment are triggered again, the company will follow the procedures outlined in the prospectus for the convertible bonds and fulfill its disclosure obligations [2].